RxDoctor Payments Data

Hiroko Noda Heiny, MD

Cardiovascular Disease · Greenfield, INNPI 1659340354

Payments from drug & device makers

$1,390in general payments, 2019–2025

Across 70 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$407
  • E.r. Squibb & Sons, L.L.C.$302
  • Abbott$169
  • Novartis$124
  • Amgen$112
  • Amarin Pharma, Inc.$78
  • plus $198 from 4 others

What the payments were for

  • Food & beverage$1,36798%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,390 in reported general payments places this provider in the 35th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$95,418
Medicare patients
442
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban264$311,767
EntrestoSacubitril/Valsartan111$133,116
XareltoRivaroxaban82$111,885
JardianceEmpagliflozin20$22,362
Repatha SureclickEvolocumab11$10,396
Metoprolol Succinate443$5,478
Bisoprolol Fumarate85$2,521
ClopidogrelClopidogrel Bisulfate126$1,336
Rosuvastatin Calcium171$1,285
Atorvastatin Calcium131$1,225
Pantoprazole Sodium139$1,088
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,084
Carvedilol100$1,048
Losartan Potassium112$973
Dofetilide16$914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$311,767264 claims
NovartisEntresto$124$133,116111 claims
Johnson & JohnsonXarelto$407$111,88582 claims
Boehringer IngelheimJardiance$74$22,36220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Greenfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →